Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies
Giancarlo Comi, Raed Alroughani, Aaron L Boster, Ann D Bass, Regina Berkovich, Oscar Fernandez, Ho Jin Kim, Volker Limmroth, Jan Lycke, Richard AL Macdonell, Basil Sharrack, Barry A Singer, Patrick Vermersch, Heinz Wiendl, Tjalf Ziemssen, Alan Jacobs, Nadia Daizadeh, Claudio E Rodriguez, Anthony Traboulsee
Multiple Sclerosis Journal | SAGE PUBLICATIONS LTD | Published : 2019
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Editorial support for the development of this paper was funded by Sanofi. The CARE-MS, CAMMS03409, and TOPAZ studies were funded by Sanofi and Bayer HealthCare Pharmaceuticals.